Savara Inc
No enriched coverage for $SVRA in the last 7 days.
No SEC Form 4 filings for $SVRA in the last 30 days.
Savara Inc. (SVRA) reported a Q1 per-share loss of $-0.15, which is wider than the FactSet estimate of a $-0.13 loss. The clinical-stage biopharmaceutical company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara's first-quarter net loss has widened due to increased research and development costs. The article, sourced from Reuters via Refinitiv, is a concise report on the company's financial performance for Q1.
Savara Inc. (Nasdaq: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced its management team will attend the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference. They will participate in a fireside chat on May 19th at the NASDAQ headquarters. A live webcast and replay will be available on the company’s corporate website for 90 days.
